Aerie Pharmaceuticals Inc. Common Stock (NASDAQ:AERI)

Home >> Stock >> Aerie Pharmaceuticals Inc. Common Stock >> Metrics

Aerie Pharmaceuticals is a commercial-stage company focused on the development and commercialization of eye disease therapies including glaucoma and other eye-diseases.'In 2017, Aerie received FDA approval for its lead drug, Rhopressa, for the lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Rhopressa is a once-daily formulation for IOP in patients suffering from open-angle glaucoma and ocular hypertension. The FDA also approved Rocklatan, a once-daily, quadruple action fixed-dose combination of Rhopressa and Xalatan. Glaucoma is one of the largest segments in the global ophthalmic market.'In addition, the company is developing sustained-release implants focused on retinal indications. These include AR-13503 (Rho kinase and Protein kinase C inhibitor implant) for macular edema due to retinal vein occlusion(RVO) and AR-1105 (dexamethasone steroid implant) for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).'...

+See More

Blog+More

Top 4 U.S. richest people are self-made billionaires: Gates, Buffet, Bloomberg, and Zuckerberg.

Dan Rochefort

2017-08-01 09:40:00 Tuesday ET

Top 4 U.S. richest people are self-made billionaires: Gates, Buffet, Bloomberg, and Zuckerberg.

In American states, all of the Top 4 richest people are self-made billionaires: Bill Gates in Washington, Warren Buffett in Nebraska, Michael Bloomberg in N

+See More

Fundamental value investors find it more difficult to ferret out individual stocks.

James Campbell

2017-06-03 05:35:00 Saturday ET

Fundamental value investors find it more difficult to ferret out individual stocks.

Fundamental value investors, who intend to manage their stock portfolios like Warren Buffett and Peter Lynch, now find it more difficult to ferret out indiv

+See More

Colin Camerer, George Loewenstein, and Matthew Rabin assess the recent advances in the behavioral economic science.

James Campbell

2023-09-14 09:28:00 Thursday ET

Colin Camerer, George Loewenstein, and Matthew Rabin assess the recent advances in the behavioral economic science.

Colin Camerer, George Loewenstein, and Matthew Rabin assess the recent advances in the behavioral economic science. Colin Camerer, George Loewenstei

+See More

Chinese President Xi JingPing calls President Trump to reach Sino-American trade conflict resolution.

Monica McNeil

2019-01-04 11:41:00 Friday ET

Chinese President Xi JingPing calls President Trump to reach Sino-American trade conflict resolution.

Chinese President Xi JingPing calls President Trump to reach Sino-American trade conflict resolution. Xi sends a congratulatory message to mark 40 years sin

+See More

What is our asset management strategy?

Andy Yeh Alpha

2027-11-23 09:24:00 Tuesday ET

What is our asset management strategy?

AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors. As of August 2026, we have u

+See More

Larry Summers critiques that the Trump tax holiday for U.S. multinational corporations may cause inadvertent consequences.

Rose Prince

2017-01-17 12:42:00 Tuesday ET

Larry Summers critiques that the Trump tax holiday for U.S. multinational corporations may cause inadvertent consequences.

Former Treasury Secretary and Harvard President Larry Summers critiques that the Trump administration's generous tax holiday for American multinational

+See More